Shanghai Junshi Biosciences Co.Ltd(688180) : the fourth generation EGFR inhibitor js113 obtained the notice of acceptance of drug clinical trial application

Shanghai Junshi Biosciences Co.Ltd(688180) announced that the holding subsidiary Suzhou JunJing Biomedical Technology Co., Ltd. received the acceptance notice approved and issued by the State Drug Administration, and the clinical trial application of the fourth generation EGFR inhibitor wj13404 tablets (project code “js113”) was accepted.